Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).
Carmen Escuriola Ettingshausen, Robert F Sidonio
https://pubmed.ncbi.nlm.nih.gov/34589194/Actively Recruiting
Led by Emory University · Updated on 2026-09-23
120
Participants Needed
2
Research Sites
26 weeks
Total Duration
Researchers are studying different ways to manage male patients with hemophilia A who have developed inhibitors to factor VIII FVIII treatment. Hemophilia A is a serious bleeding disorder caused by a lack of FVIII, leading to frequent bleeding episodes and joint damage. Some patients develop inhibitors that reduce the effectiveness of FVIII replacement therapy. This observational study aims to document current immune tolerance induction ITI methods and evaluate the safety and effectiveness of ITI, including when combined with emicizumab, a newer therapy. Participants will be grouped based on their treatments one group receives ITI with Nuwiq, octanate, or wilate, with bypassing agents like aPCC or rFVIIa as needed another group receives ITI combined with emicizumab and bypassing agents the third group receives routine prophylaxis with emicizumab or bypassing agents without ITI. Treatment doses are decided by the investigators based on patient condition. Participants may switch groups if their treatment changes and will be observed for up to five years. Throughout the study, participants will be monitored for inhibitor levels, FVIII recovery and half-life, and annual bleeding rates. Researchers will also track the use and frequency of emicizumab and bypassing agents, bleeding severity, surgical bleeding, adverse reactions, thrombotic events, and treatment costs. Data collection will occur regularly over the five-year period to understand long-term outcomes and safety.
CONDITIONS
Treatment of Hemophilia A Patients With FVIII Inhibitors
R
Robert Sidonio, MD, MSc
C
Carmen Escuriola-Ettingshausen, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Emory University
Lead Sponsor
Octapharma
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants are observed while receiving their usual treatment based on their group assignment. Researchers collect data on treatments, bleeding episodes, inhibitor levels, and safety over time.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Carmen Escuriola Ettingshausen, Robert F Sidonio
https://pubmed.ncbi.nlm.nih.gov/34589194/Emory University
Lead Sponsor
Octapharma
Collaborating Sponsor